Bupropion Hydrochloride Tablet, Extended Release
Product Images NDC 76282-481

This is a medication with the brand name Exelan. It contains bupropion hydrochloride, USP in extended-release tablets of 150mg each. It is not advisable to use it with ZYBAN® or any other medication that has bupropion HCI. Children should not be allowed to take it. It is recommended to keep it at room temperature. Each patient should receive a medication guide. The manufacturer is InvaGien Pharmaceuticals, Inc., a subsidiary of Cipla Ltd., Hauppauge, NY 11788, and it is manufactured for Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432.*

This is a description of a medication called "buPROPion HCI" in the form of extended-release tablets. Each tablet contains 150 mg of bupropion hydrochloride, USP. It is supposed to be taken once a day or as directed by a physician. There is a warning not to use it in combination with ZYBAN® or any other medicines that contain bupropion HCL. The pharmacist should provide a medication guide to each patient. The medication should be kept out of the reach of children and stored at 20° to 25°C (68° to 77°F). The package insert should be consulted for full prescribing information. The medication was manufactured by InvaGen Pharmaceuticals, Inc. for Exelan Pharmaceuticals, Inc. It comes in a bottle with 500 tablets.*

This is a warning label and medication guide for once-daily extended-release 150mg tablets of buPROPion HCI. The medication should not be used in combination with ZYBAN or other bupropion-containing medicines. The pharmacist should dispense a separate medication guide to each patient. The medication should be kept out of the reach of children and stored at controlled room temperature. The usual dosage is one tablet daily, or as directed by a physician. This product is manufactured by InvaGen Pharmaceuticals, a subsidiary of Cipla Ltd, and distributed by Exelan Pharmaceuticals.*

This is a medication for oral use, named buPROPion Hydrochloride (HCI) Extended-release Tablets, USP (XL), with a strength of 300 mg per tablet. It is for once-daily consumption or as per directed by a physician. The medication guide should be given to each patient by the pharmacist. It must not be used in combination with ZYBAN or any other drug containing bupropion HCIL. The tablets should be stored between 20°C to 25°C in a controlled environment. This medicine can't be used by children. ZYBAN is a trademark of GlaxoSmithKline. The tablets are manufactured by InvaGen Pharmaceuticals, Inc., a subsidiary of Cipla Ltd, Hauppauge, NY 11788, for Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432.*

Once-Daily Bupropion HCI Extended-release Tablets, USP (XL) is a medication for which each extended-release tablet contains 300 mg of bupropion hydrochloride, USP, and is not recommended to be combined with ZYBAN® or any other medicines that contain bupropion HCI. It is advised that the Medication Guide is provided to each patient by the pharmacist. The drug should be kept out of children's reach and stored within a temperature range of 20°C to 25°C (66°F to 77°F) as specified by USP Controlled Room Temperature. The drug's typical dosage is one tablet daily or as prescribed by the physician, and the package insert should be consulted for complete prescribing information. The product is manufactured by InvaGen Pharmaceuticals, Inc., for Exelan Pharmaceuticals, Inc. in Boca Raton, FL. The software also captured numerous special characters and false spaces, which have been excluded from the description.*

This is a medication with the brand name "buPROPion HCI Extended-release Tablets, USP (XL)" with a warning against using it with ZYBAN or other medicines containing bupropion HCI. It is advised to dispense the medication guide provided separately to each patient. The medication is available in the form of 90 tablets, and each tablet contains 300 mg of bupropion hydrochloride, USP. It is recommended to keep the medication out of the reach of children and store it at 20°to 25°C (68°to 77°F). The usual dosage is to take one tablet daily or as directed by a physician. It also mentions the manufacturer and the registered trademark of the medication, which is ZYBAN.*